Stablepharma

Last updated
Stablepharma Ltd
Company typePrivate
Industry Biopharmaceutical
Founded2012
FoundersNick Child & Dr Bruce Roser
Headquarters
Bath and North East Somerset
,
United Kingdom
Area served
Worldwide
Website www.stablepharma.com

Stablepharma Ltd is a UK-based biopharmaceutical company known for developing a range of fridge-free vaccines using its branded technology to eliminate the need for the global cold chain and reduce the global vaccine wastage. [1] [2]

Contents

Stablepharma was the winner of the 2024 Fierce Life Sciences Innovation Biotech Award [3] and a finalist for the Pharma Industry Awards UK 2024 Biotech of the year. [4]

History

Stablepharma was founded in 2012 after the company’s Chairman and Founder, Dr Bruce Roser identified and patented the process of using Trehalose to achieve a state of suspended animation in a sugar glass to thermally stabilise a range of vaccines. [5] [6]

In September 2023, Stablepharma secured a second Innovate UK Grant, in partnership with the University Hospital of Southampton NHS Foundation Trust to commence a bridge-funding round. [7]

On the 18th of December 2024, Stablepharma submitted a Clinical Trial Application (CTA) to the UK regulators, Medicines and Healthcare products Regulatory Agency (MHRA), for a trial with SPVX02, a booster vaccine for the prevention of tetanus and diphtheria infection. [8] The submission of the CTA represents a significant milestone for Stablepharma and secures its positioning as a clinical-stage biotechnology company. [8]

Vaccine technology

Stablepharma offers a technology platform known as StablevaX which has been designed to meet the criteria for usage required by the World Health Organization (WHO) and its use in the field for immunisation programmes requires limited or no training. [9]

In collaboration with EU manufacturer BB-NCIPD Ltd (Bul Bio), Stablepharma is producing a fridge-free Tetanus diphtheria (SPVX02) vaccine, a pharmaceutical product for the prevention of Tetanus and Diphtheria and also a fridge-free Tetanus (SPVX06) vaccine for the prevention of Tetanus. [10]

Award and honors

References

  1. ↑ "Fridge-Free COVID-19 Vaccines a Possibility". genengnews.com. 14 December 2021. Retrieved 23 January 2025.
  2. ↑ Kate Robinson& Laura Elizabeth Lansdowne, "Developing Thermostable Vaccines To Improve Accessibility Worldwide". technologynetworks.com. 26 July 2021. Retrieved 23 January 2025.
  3. ↑ "Stablepharma named life sciences innovation awards winner". bioindustry.org. 6 December 2024. Retrieved 23 January 2025.
  4. 1 2 "Innovation takes centre stage at Pharma Industry Awards UK 2024". thetimes.com. 11 December 2024. Retrieved 23 January 2025.
  5. ↑ Angeli Mehta, "Can chemistry thaw the vaccine cold chain?". chemistryworld.com. 19 January 2021. Retrieved 23 January 2025.
  6. ↑ "The imperative of fridge-free vaccines". europeanpharmaceuticalreview.com. 19 December 2023. Retrieved 23 January 2025.
  7. ↑ "Stablepharma secures Innovate UK grant, bridge funding round to launch". bioindustry.org. 26 September 2023. Retrieved 23 January 2025.
  8. 1 2 "Stablepharma achieve significant milestone in the GMP manufacture of a fridge-free Td vaccine". stablepharma.com. 19 June 2024. Retrieved 23 January 2025.
  9. ↑ Ronan Leonard, "Stablepharma Ltd and BB-NCIPD Ltd produce the world's first fridge free Tetanus diphtheria vaccine". irishtechnews.ie. 30 March 2021. Retrieved 23 January 2025.
  10. ↑ Ronan Leonard, "Stablepharma and Partner BB-NCIPD Ltd (Bul Bio) sign a second exclusive supply agreement to develop a fridge-free Tetanus mono vaccine". irishtechnews.ie. 5 May 2023. Retrieved 23 January 2025.
  11. ↑ "2024 Fierce Life Sciences Innovation Awards Winners". fiercelifesciencesinnovationawards.fiercelifesciences.com. Retrieved 23 January 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.